The brim of uncertainty in adjuvant treatment of melanoma

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, 300 East 66th Street, New York, NY 10065, USA. Electronic address: postowm@mskcc.org.

Comment

Allison Betof Warner et al. Lancet Oncol. 2018 Apr.

. 2018 Apr;19(4):436-437.

doi: 10.1016/S1470-2045(18)30150-5. Epub 2018 Feb 21.

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, 300 East 66th Street, New York, NY 10065, USA. Electronic address: postowm@mskcc.org.

No abstract available

Comment on

Adjuvant vemurafenib in resected, BRAF^V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators. Maio M, et al. Lancet Oncol. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21. Lancet Oncol. 2018. PMID: 29477665 Clinical Trial.